Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arecor Therapeutics's revenue for the
six
months ended in Dec. 2025 was €-0.33 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €2.03 Mil.
Arecor Therapeutics's Revenue per Share for the
six
months ended in Dec. 2025 was €-0.01.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.05.
Warning Sign:
Arecor Therapeutics PLC revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Arecor Therapeutics was -12.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -19.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -3.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 9 years, Arecor Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 45.40% per year. The lowest was -19.70% per year. And the median was 0.70% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Arecor Therapeutics Revenue Related Terms
Arecor Therapeutics Revenue Historical Data
* Premium members only.
The historical data trend for Arecor Therapeutics's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arecor Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arecor Therapeutics Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's Revenue distribution charts can be found below:
* The bar in red indicates where Arecor Therapeutics's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arecor Therapeutics (STU:6UI) has a Revenue of €2.03 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Arecor Therapeutics and its competitors.
Is Arecor Therapeutics' Revenue too high?
Arecor Therapeutics' current Revenue is €2.03 Mil. Overall, Arecor Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' Revenue compare to VRTX and REGN?
Arecor Therapeutics' Revenue of €2.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Arecor Therapeutics and its competitors. Arecor Therapeutics's current Revenue is €2.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Arecor Therapeutics (STU:6UI) has a current Revenue of €2.03 Mil. The stock's GF Value™ is €0.49, compared to a current price of €0.69 — trading 39.8% above its estimated fair value. The current Revenue is €2.03 Mil. Arecor Therapeutics' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Arecor Therapeutics (STU:6UI), the current Revenue is €2.03 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arecor Therapeutics (STU:6UI) Overvalued in 2026?
Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued.
The current stock price of €0.69 is trading 39.8% above its estimated GF Value™ of €0.49.
Key valuation signals for STU:6UI:
Revenue: €2.03 Mil
GF Value™: €0.49 vs. price of €0.69 (39.8% above fair value)
No single metric tells the full story. See the STU:6UI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
37GF Score
Get the complete analysis for STU:6UI
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6UI has been successfully added to your 
